Pelham, NH, United States of America

Robert Schaub


Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2012-2013

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Inventor Robert Schaub in Bleeding Disorder Therapeutics

Introduction: Robert Schaub is an innovative inventor based in Pelham, NH, USA. With a remarkable portfolio of three patents, Schaub has contributed significantly to the field of nucleic acids, particularly in developing therapeutics for bleeding disorders. His work emphasizes the importance of innovation in medicine, creating solutions that can improve patient outcomes and address critical health challenges.

Latest Patents: One of Schaub's latest patents focuses on "Aptamers to Tissue Factor Pathway Inhibitor and Their Use as Bleeding Disorder Therapeutics." This invention relates to aptamers that bind to Tissue Factor Pathway Inhibitor (TFPI), which are beneficial in diagnosing and treating bleeding disorders and other related diseases. The aptamers can be utilized before, during, and after medical procedures, potentially reducing complications and side effects associated with these interventions. Additionally, the patent encompasses various materials and methods for effectively administering the TFPI binding aptamers.

Career Highlights: Throughout his career, Robert Schaub has been associated with prominent companies such as Baxter International Inc. and Baxter Healthcare. His experiences in these organizations have allowed him to refine his skills in research and innovation, contributing to advancements in medical therapeutics.

Collaborations: Schaub has worked alongside talented individuals like Kathleen McGinness and Jennifer Nelson, with whom he has collaborated to enhance his research efforts. These partnerships have played a significant role in developing his innovative solutions and patents.

Conclusion: Robert Schaub exemplifies the spirit of innovation, particularly in the biomedical field. His patents for aptamers targeting Tissue Factor Pathway Inhibitor showcase his commitment to addressing complex medical issues. Through his work, Schaub continues to pave the way for advanced therapeutics that can significantly benefit patients with bleeding disorders and improve the overall landscape of medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…